Status:
COMPLETED
Inhaled Steroid Reduces Systemic Inflammation in COPD
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Chronic Obstructive Pulmonary Disease
Emphysema
Eligibility:
All Genders
40-80 years
Phase:
PHASE4
Brief Summary
Systemic inflammation is present in chronic obstructive pulmonary disease (COPD), which has been linked to cardiovascular morbidity and mortality. We determined the effects of oral and inhaled cortico...
Detailed Description
We recruited patients aged 45 to 80 years, who had stable symptoms of COPD in the previous 3 months before study entry. All patients had a forced expiratory volume in one second (FEV1) after bronchodi...
Eligibility Criteria
Inclusion
- stable symptoms of COPD in the previous 3 months before study entry; forced expiratory volume in one second (FEV1) after bronchodilation with 400 mcg salbutamol that was 25 to 90% of predicted, a change of less than 20% of predicted FEV1, 30 minutes following bronchodilation, and a FEV1/forced vital capacity (FVC) of less than 75%; history of at least 10 pack-years of smoking or prolonged exposure (\>10 years) to noxious gases (e.g. diesel fumes).
Exclusion
- active malignancy; unable to follow instructions; patients taking any anti-inflammatory medications
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
End Date :
July 1 2003
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00175565
Start Date
January 1 2002
End Date
July 1 2003
Last Update
July 28 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta
Edmonton, Alberta, Canada, T6G 2R7
2
University of British Columbia
Vancouver, British Columbia, Canada, V6Z 1Y7